Abstract
Taiwan has chosen to promote drug development as a strategic industry in the coming years. The development and implementation of good clinical practice (GCP) is an essential step for Taiwan to be part of the global pharmaceutical market. This paper covers the development and implementation of GCP in Taiwan, which has started a revolution in every aspect of clinical trials.
Get full access to this article
View all access options for this article.